Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22246018 | 0.86 | PTGS1 (0.53) | KMT2AHSD17B1HSD17B2PTGS1PTGS2 | |
| SCHEMBL22246145 | 0.86 | HSD17B1 (0.57) | KMT2AHSD17B1HSD17B2PTGS2 | |
| SCHEMBL26200506 | 0.86 | KMT2A (0.40) | KMT2AHSD17B1HSD17B2PTGS1PTGS2 | |
| SCHEMBL22246010 | 0.85 | KMT2A (0.59) | KMT2AHSD17B1HSD17B2PTGS1PTGS2 | |
| SCHEMBL22246041 | 0.84 | KMT2A (0.45) | KMT2APTGS1PTGS2PGR | |
| SCHEMBL22246139 | 0.82 | PTGS2 (0.51) | PTGS1PTGS2 | |
| SCHEMBL6350545 | 0.82 | KMT2A (0.56) | KMT2APTGS1PTGS2CYP19A1 | |
| SCHEMBL22246045 | 0.81 | PRF1 (0.37) | KMT2APTGER1PTGS2 | |
| SCHEMBL22246144 | 0.79 | PRF1 (0.45) | KMT2AHSD17B1HSD17B2PTGS1PTGS2 | |
| SCHEMBL22246020 | 0.79 | PTGS1 (0.57) | KMT2APTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744826-B2 | Compounds and methods of treating retinal degeneration | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220087992-A1 | COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | disclosed |
| US-11191752-B2 | Compounds and methods of treating retinal degeneration | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200230119-A1 | COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION | CASE WESTERN RESERVE UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087992-A1 | COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | KMT2A 4688/4885HSD17B1 313/4885HSD17B2 272/4885 |
| US-20200230119-A1 | COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION | PDE6A, PDE6H, PDE6D | KMT2A 4586/4885HSD17B1 640/4885HSD17B2 860/4885 |
| US-11744826-B2 | Compounds and methods of treating retinal degeneration | ALDH1A2, PDE6D, PDE6C | KMT2A 4688/4885HSD17B1 313/4885HSD17B2 272/4885 |
| US-11191752-B2 | Compounds and methods of treating retinal degeneration | PDE6A, PDE6H, PDE6D | KMT2A 4586/4885HSD17B1 640/4885HSD17B2 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.